SCIENTISTS PREDICT

THE 21ST CENTURYIS THE ERA OF CELL THERAPY

Globally Recognized Efficacy

Stem cells and regenerative medicine are expected to become the "golden key" for deciphering the code of life and unlocking cures for serious and intractable diseases. There are more than 7,500 ongoing stem cell clinical studies worldwide, with 15 stem cell drugs already approved for marketing.

Yuanpin Biotech, Leading Through R&D to Address Unmet Medical Needs in China's Bio-pharmaceutical Industry

The company follows a development strategy known as "One Body, Dual Wings, and Triple Engines": stem cell drug R&D and clinical translation form the Body; stem cell and immune cell storage services represent the Dual Wings; and R&D, marketing, and capital operations drive the Triple Engines.

Proprietary Core Technologies, Focusing on Serious and Intractable Diseases

Since 2004, Professor Wang Jian's technical team has conducted clinical studies in nearly 40,000 cases using human umbilical cord mesenchymal stem cell formulations and human amniotic mesenchymal stem cell formulations. Professor Zhigang Xue's team employed single-cell RNA sequencing technology to decipher cell subpopulations and their mechanisms of action, with findings published in top-tier international journals including Nature.

Targeting global scientific frontiers, our company focuses on treating serious and intractable diseases by leveraging our proprietary single-cell subpopulation typing combined with high-throughput sequencing technologies. We found that mesenchymal stem cells from diverse genetic backgrounds and tissue sources consist of different stem cell subpopulations. These subpopulations act through different mechanisms to address different diseases. Utilizing Yuanpin Biotech's proprietary preparation process, we can produce specialized stem cell formulations enriched with specific subpopulations, delivering unique therapeutic effects for specific diseases.

Ongoing Research Projects: